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ABSTRACT 
Helicobacter pylori (H. pylori) infection increases stomach cancer risk. The aim of this 
thesis was to study genetic susceptibility from the host and to develop molecular 
methods for future characterization of bacterial virulence factors in longitudinal 
cohorts.  
 
In Study I, we investigated the association between genetic variation in an O-glycan 
transferase encoding gene (a4GnT) and H. pylori infection and gastric cancer risk in a 
Polish population-based case–control study (273 gastric cancer patients and 377 
controls). A haplotype at rs2622694–rs397266 was associated with 
H. pylori infection, with the A-A haplotype associated with a higher risk compared 
with the most frequent G-G haplotype (odds ratio 2.30; 95% confidence intervals 1.35–
3.92). Neither this haplotype nor the tagSNPs were associated with overall gastric 
cancer risk. 
 
In Study II, we characterized genomic evolution of H. pylori over 20 years in the 
stomach. Whole genome of 21 sequential isolates 20 years apart, from 7 patients, were 
sequenced using 454 sequencing platform. There were on average 260 point mutations 
(range 70 to 488) per isolate over 20 years, and 45 recombinations (range 18 to 92). 
Genes in the cell motility category were overrepresented in point mutations and 
recombinations. Specifically, mutations often affected genes involved in chemotaxis, 
vacuolating cytotoxin-like protein, restriction and type IV secretory pathway; and 
recombinations affected glycosyltransferase involved in lipopolysaccharide 
biosynthesis. The major form of single nucleotide substitutions was transition (85%) 
and the minor form was transversion (15%). Mutation was sequence context-
dependent. 
 
Clinical samples are often precious and of trace amounts. In Study III, we developed 
novel methods for DNA shotgun library construction and quantification. As compared 
with the standard procedure, our double-stranded and Y library construction methods 
are simpler and more efficient. A highly sensitive Taqman MGB-probe-based 
quantitative polymerase chain reaction (qPCR) was developed to quantify the amount 
of effective library. We also demonstrated that the distribution of library molecules on 
capture beads follows a Poisson distribution. Combining the qPCR and Poisson 
statistics, the labor intensive and costly titration can be eliminated and trace amounts of 
starting material is applicable.  
 
Archived formalin-fixed and paraffin-embedded (FFPE) biopsies, coupled with long 
term follow-up, are valuable resources for molecular epidemiologic studies. Study IV 
presented a method based on laser capture micro-dissection and modified whole 
genome sequencing methods to obtain metagenomic profiles of H. pylori from 15-year 
old FFPE biopsy sections.  
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1 INTRODUCTION 
 
Although the age-standardized incidence of stomach cancer has been declining over 
recent decades, this cancer is still the fourth most common cancer (7.8% of all cancers) 
and the second leading cause of cancer-related mortality (9.7% of all cancer deaths) 
worldwide [1]. Nearly one million new stomach cancer cases happened in 2008 and the 
number is estimated to increase by 76% in 2030, largely due to aging population [1]. 
Helicobacter pylori (H. pylori) colonizes about half of the world population [2] and 
contributes to about 60% to 90% of stomach cancers [3].  
 
H. pylori has been defined as a strong risk factor for gastric cancer, but only a small 
subset of infected individuals develop gastric cancer [4]. The magnitude of the risk 
varies in different parts of the world, to get a hint, 4.7% of infected adults (mean age 
52) with non-ulcer dyspepsia in Japan developed gastric cancer over 7.8 years [5]. 
Individuals having duodenal ulcer, which is one of the sequelae of H. pylori infection, 
however are protected from gastric cancer, observed both in Sweden [6] and in Japan 
[5]. The underlying mechanisms why the infection in the majority has benign course 
whereas a subset of H. pylori-colonized persons develop different outcomes that are 
mutually exclusive are not known [4,7]. 
 
 2 
2 BACKGROUND 
 
2.1 DESCRIPTIVE EPIDEMIOLOGY 
2.1.1 Stomach cancer 
 
 
 
Figure 2.1 Global stomach cancer incidence: estimated age-standardized incidence rate per 100,000, by 
sex, all ages. Source: GLOBOCAN 2008 (IARC) 
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Stomach cancer was the most common cancer in the first estimate of global cancer 
incidence in 1975, and was behind lung, breast and colorectum in 2008. About 50% of 
stomach cancers occur in Eastern Asia, mainly in China [1]. Age-standardized 
incidence rates were about twice as high in men as in women, ranging from 3.9 in 
Northern Africa and 5.8 in Northern America to 42.4 in Eastern Asia for men, and from 
2.2 in Southern Africa and 2.8 in Northern America to 18.3 in Eastern Asia for women 
[1] (Figure 2.1). Overall, the incidence of stomach cancer has declined in the past 
decades in both high-risk [8,9] and low-risk areas [10]. 
 
Stomach cancer has poor survival and is the second leading cause of cancer death in 
both sexes worldwide, after lung cancer [1]. The highest mortality rates are estimated in 
Eastern Asia (28.1 per 100,000 in men, 13.0 per 100,000 in women) and a low 
mortality in Northern America (2.8 per 100,000 in men, 1.5 per 100,000 in women). 
Five-year relative survival rates approximate 20% in most areas of the world, except in 
Japan where it approaches 60% owning mostly to a mass screening program, different 
staging system, and early treatment [8]. 
 
2.1.2 Subtypes of stomach cancer 
More than 95% of all gastric neoplasms are adenocarcinomas. H. pylori infection 
causes gastric mucosa associated lymphoid tissue (MALT) lymphoma, which could be 
regressed totally by eradication of H. pylori [11]. This thesis focused on gastric 
adenocarcinoma. 
 
 
Figure 2.2 Anatomy of the stomach 
 
2.1.2.1 Cardia, non-cardia, and corpus 
By anatomy sites, gastric adenocarcinomas can be divided into cardia and non-cardia. 
Cardia cancer has been defined as an adenocarcinomatous lesion with its center located 
within 1 cm proximal and 2 cm distal to the esophagogastric junction [12,13] (Figure 
2.2). A less precise definition based on ICD-O code (9th version 151.0 and 10th version 
C16.0) has also been used [14,15,16]. Rising incidence of cardia cancer was first 
reported in the United State in 1991 [16]. One of the explanations was misclassification 
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of esophageal adenocarcinoma as cardia cancer [13], as suggested by a study showing 
stable incidence of cardia cancer identified by meticulous site-specific diagnosis in 
Sweden [17]. No increase in cardia cancer was noted in Eastern Asia [18,19]. The 
overall decline in stomach cancer incidence worldwide was due to a decline in non-
cardia cancer. The incidence of non-cardia cancer declined among all ethnics and age 
groups in the United States from 1977 through 2006, except for whites aged 25 to 39 
years, for whom it increased [20]. Very recently, among non-cardia cancers, corpus 
cancer was suggested to be an epidemiologically distinct entity from the rest of non-
cardia cancers [21]. In the United States, between 1976 and 2007, corpus cancer 
incidence rate increased by 1% annually for whites and 3.5% for blacks, and decreased 
among other ethnics. In a larger but newer database, corpus cancer significantly 
increased between 1999 and 2007 among younger and middle-aged whites [21]. 
 
2.1.2.2 Intestinal and diffuse types 
Dr. Laurén subdivided gastric adenocarcinoma into two main histological types, 
intestinal type and diffuse type, in 1965 [22]. The intestinal type gastric cancer is 
mainly diagnosed in the elderly and diffuse type in younger age groups. The intestinal 
type gastric cancer has a long incubation time – about 30 to 50 years and typically 
evolves from chronic gastritis to atrophic gastritis, intestinal metaplasia, dysplasia and 
adenocarcinoma – as proposed in the Correa model in 1975 [23]. The intestinal type is 
more common than diffuse type, and there also exist some tumors showing features of 
both. The declining gastric cancer incidence during the past decades was attributable to 
the decreasing incidence of the intestinal type in both high-risk and low-risk areas [24]. 
A population-based and comprehensive case ascertainment study conducted in Sweden 
showed that, among non-cardia cancers, the age-standardized incidence of the intestinal 
type was 7.9, 6.8 and 5.1 per 100,000 person-years in 1989-1990, 1991-1992 and 1993-
1994, respectively [17]. The corresponding figures for the diffuse type were 4.5, 4.5 
and 3.2 per 100,000 person-years.  
 
2.1.3 Prevalence of H. pylori infection 
H. pylori colonizes the stomach of about half of the world’s population [25,26]. The 
prevalence of H. pylori infection has declined during the last decades, but varies greatly 
in different countries, age groups and socioeconomic classes [27,28,29]. The 
prevalence among middle-aged adults ranges from over 80% in the developing 
countries to 20% - 50% in the industrialized countries [25]. A recent larger study 
involving 7,465 adults in the US showed that the sero-prevalence of H. pylori was 
32.5% overall, and was 52.7% among non-Hispanic blacks, 61.6% among Mexican-
Americans, and 26.2% among non-Hispanic Caucasians [30]. In Eastern Asia, the 
sero-prevalence ranges from about 80% to 90% in India and Bangladesh, to 60% in 
China and Korea, and 40% in Japan [29]. 
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The infection is acquired early in childhood through person-to-person transmission 
[31]. Culturing for H. pylori using the air sampled 0.3 meter away from healthy carriers 
of H. pylori during vomiting could grow positive colonies [32]. By the age of 15 years 
the sero-prevalence,  as determined by the immunoblot assay, was estimated to 
decrease from 43% in the 1950s, to 36% in the 1960s and 30% in the 1970s in the 
United Kingdom [28]. In the Dutch population, age 12 -15 years, the sero-prevalence 
determined by ELISA of anti-H. pylori IgG antibodies decreased from 23% in 1978 to 
11% in 1993 [27]. The decline suggested a birth-cohort effect, reflecting improvement 
in hygienic conditions and decreased crowding during childhood for younger 
generations [27,28]. 
 
 
2.2 STOMACH CANCER RISK FACTORS 
Environmental and lifestyle factors may play important roles in the risk for gastric 
cancer. A recent review concluded that high intake of fresh fruits and vegetables, 
lycopene and its products, and potentially vitamin C and selenium may be protective 
[33]. In addition to H. pylori infection, suggested risk factors include high intake of 
nitrosamines, processed meat products, salt and salted foods, and smoking [33,34]. 
There is little evidence to support the associations between β-carotene, vitamin E, 
alcohol consumption and the  risk for gastric cancer [33]. This thesis focused on host 
genetic polymorphisms and the genomics of H. pylori. 
 
2.2.1 Host genetic susceptibility 
A large-scale twin study in northern Europe estimated that heritability accounts for 
28% of the variation in susceptibility to gastric cancer [35]. Hereditary diffuse gastric 
cancer (HDGC) is an autosomal-dominant disease characterized by aggressive and 
poorly differentiated carcinoma due to g rmline mutations in the CDH1 gene which 
encodes a tumor suppressor intercellular adhesion protein E-cadherin [36].  
 
Other main approaches used to identify the associations between single nucleotide 
polymorphisms (SNPs) and diseases include the hypothesis-driven candidate gene 
approach and hypothesis-free genome-wide association study (GWAS). 
 
2.2.1.1 Candidate gene approach 
Many studies on genetic susceptibility to gastric cancer have been conducted. A 
systematic review of meta-analyses was performed focusing on nine genes involved in 
inflammation (IL-1β, IL-1RN, IL-8), detoxification of carcinogens (GSTs, CYP2E1), 
folate metabolism (MTHFR), intercellular adhesion (E-cadherin) and cell cycle 
regulation (p53) [37]. In the estimations of population attributable risks (PAR, which is 
e
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the proportion of gastric cancer cases attributable to the presence of the variant 
genotype), the most impacting polymorphisms were E-cadherin -160A and IL-1 -511T 
(which might account for ~20% among Caucasians), MTHFR -677T variant and 
GSTM1 null (both 10% in Asians and Caucasians), IL-1RN *2 (10% in Caucasians) and 
IL-8 -251A (10% in Asians) [37].  
 
Relatively few studies of genetic susceptibility have focused on host responses to H. 
pylori within the gastric mucus. The gel layer covering the gastric mucosa is the major 
reservoir of H. pylori. An uneven distribution of H. pylori among mucins of varied 
physiochemical properties, as observed by electron microscopy [38], provides clues to 
understand how the host environment may influence H. pylori survival. H. pylori rarely 
colonize the deeper portions of the normal gastric mucosa [38,39], where the mucins 
are rich in O-glycans capped with terminal alpha-1,4-linked N-acetylglucosamine 
(A4GN) [40,41].  Glycans possessing this A4GN residue, but not those without, 
suppress H. pylori growth in vitro [42,43]. The transfer of A4GN to beta-Gal residues 
with alpha1,4-linkage, forming GlcNAc alpha-1, 4-Gal beta-R structures, is mediated 
by a transferase encoded by the gene A4GNT [40].  
 
The histo-blood group antigen Lewis b (Leb), which is dominant antigen in the gastric 
mucosa, was identified to function as a receptor for H. pylori [44]. The MUC5AC, a 
highly glycosylated protein in the mucus, was suggested as the primary receptor for H. 
pylori [45]. In the Portuguese population, which has a relatively high stomach cancer 
incidence in Europe, the smaller size of MUC1 variable number tandem repeat (VNTR) 
alleles were associated with an increased risk for gastric carcinoma [46], as well as 
chronic atrophic gastritis and incomplete intestinal metaplasia [47]. In addition, the 
smaller size VNTR alleles of MUC6 have been associated with H. pylori infection [48] 
and an excess risk of stomach cancer [49]. We previously conducted one study in 
Poland and the results showed that the MUC1 haplotype ACTAA at rs4971052-
rs4276913-rs4971088-rs4971092-rs4072037 had a nearly doubled risk compared to the 
common haplotype GTAAG [50]. For MUC5AC, the minor allele at rs868903 was 
associated with an 80% increased risk of stomach cancer [50]. 
 
2.2.1.2 GWAS 
Although GWAS stands for genome wide association study, it has been typically based 
on single nucleotide polymorphism (SNP) data, i.e. SNP-based GWAS. Other forms of 
GWAS are not feasible yet. 
 
To date, the only available stomach cancer GWAS (small chips, two stages: 85,576 and 
2,880 SNPs) was from Japan and Korea. The study showed that polymorphisms 
(rs2976392 and rs2294008) in the prostate stem cell antigen gene (PSCA), which 
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possibly involves in regulating gastric epithelial-cell proliferation, influenced 
susceptibility to diffuse type gastric cancer (rs2976392: OR = 1.62, P = 1.11 x 10-9; 
rs2294008: OR = 1.58, P = 6.3 x 10-9) but not to intestinal type gastric cancer [51]. 
However, an independent validation study in China on these two specific loci showed 
that the SNP rs2976392 was associated with both intestinal and diffuse types of gastric 
cancer, and that SNP rs2294008 was not associated with gastric cancer [52]. 
 
Following their initial GWAS study [51], the authors continued to study the second 
most significant locus which was in MUC1, and included an additional MUC1 SNP 
(rs4072037) [53]. A significant association between rs4072037 and diffuse type gastric 
cancer was observed and was confirmed with functional study [53]. This was in line 
with our previous study on this SNP, only that our result pointed to an association for 
overall gastric cancer (66% intestinal type) in a Polish population [50]. 
 
2.2.2 H. pylori infection 
The International Agency for Research on Cancer (IARC) stated H. pylori as a definite 
(group I) carcinogen to human in 1994 [54]. After evaluation of new evidence, the 
IARC restated the 1994 statement in 2011 [11]. A comparison in H. pylori infection 
concordance in monozygotic and dizygotic twins estimated that hereditability may 
explain 57% of infection prevalence [55]. The infection increases risk for non-cardia 
cancer, but not for cardia cancer in Western countries [11,56,57]. However, one study 
from China reported an elevated risk for cardia cancer (hazard ratio 1.64, 95% CI 1.26 
– 2.14) [58], while another study from Japan showed a non-significant elevated risk 
[59].  
 
The magnitude of the association between H. pylori infection and non-cardia gastric 
carcinoma risk varied to a great extent in different studies. Cross-sectional studies 
reported weak association, but  prospective studies, where samples were collected 
many years before stomach cancer diagnosis, generally pointed to strong associations 
[11], for example,  an odds ratio as high as 48.5 was reported when sera were collected 
at a mean age of 31 (range 16 to 40) and cancer cases diagnosed at a mean age 47 
(range 25 to 68)  [60]. In studies where H. pylori infection was assayed by anti- H. 
pylori IgG ELISA generally an approximately doubled risk of non-cardia cancer was 
reported [11]. Immunoblot provides higher sensitivity than ELISA and is able to detect 
low-abundant antibodies that could be missed by ELISA [56]. When immunoblot was 
used to determine the infection status, the odds ratio increased to 10 - 18 [56,61], and to 
68 in one study (antibody against CagA was used) [57]. A meta-analysis of studies 
shows that CagA-positive strains increase the risk of non-cardia gastric cancer two-fold 
compared to CagA-negative strains [62]. 
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2.2.3 Antibiotic resistance 
When the Scottish bacteriologist Alexander Fleming was awarded the Nobel Prize in 
1945, he somewhat prophetically warned that misuse of penicillin would lead to 
resistance. H. pylori eradication trials have demonstrated favourable results for patients 
with peptic ulcers, pre-cancerous lesions and MALT [63,64,65,66]. After decades of 
treatment against H. pylori infection, antibiotic resistance is becoming more and more 
common [67]. Success  rate of first eradication is often less than 80% in most parts of 
the world [67]. Opinion leaders have called for a regime with a local eradication rate of 
> 90% [68]. Development of antibiotic resistance is one of the main concerns why at 
this stage widespread eradication of all H. pylori infections should not be 
recommended. 
 
 
2.3 H. PYLORI GENOMICS 
The carcinogenic action of H. pylori infection on gastric cancer is chronic, presumably 
lasts for decades, during which time profound changes typically occur in the 
microorganism’s niche [69]. In return, H. pylori may change its genomic makeup to 
adapt to the altered micro-environments. Some H. pylori pathogenic factors have been 
characterized such as the cy toxin-associated gene pathogenicity island (cagPAI) and 
vacuolating cytotoxin A (VacA) [11]. Other unexplored factors in the bacteria genome 
are likely to be important. The focus of this thesis on H. pylori was at the genome level. 
 
H. pylori genome is extremely diverse [70]. Finger printing technique – RAPD-PCR 
results demonstrated that essentially every two H. pylori isolates from different 
individuals showed different banding patterns [71,72].  
 
Traditional Sanger sequencing was used to sequenced the first H. pylori strain 26695 
from a patient with gastritis in 1997 [73] and, subsequently, strain J99 from a patient 
with duodenal ulcer in 1999 [74] and HPAG1 from a patient with chronic atrophic 
gastritis in 2005 [75]. In the past few years, many H. pylori strains (tens, or more than 
one hundred if including draft genomes) had been sequenced by the means of high-
throughput sequencing [76].  
to
   9 
 
Figure 2.3 GC content of the genome of H. pylori 26695, by 1000-bp bin 
 
In the comparison of the genomes of strain 26695 and strain J99, the segments that 
contain high proportions (46% and 48%) of genes that are unique to one of the strains 
was named plasticity zones [74].  Plasticity zone segments have low GC content (< 
35%, Figure 2.3), as opposite to a percentage of about 39% for the entire genome. A 
recent study on the plasticity zones of five more strains showed that plasticity zones are 
complex mosaics of transposable elements (TnPZ) remnants, formed by multiple TnPZ 
insertions, and spontaneous and transposable element mediated deletions [77]. They 
were not essential for the viability, but some TnPZ genes affect bacterial phenotypes 
and fitness [77]. 
 
Genomic comparison of H. pylori host jump from human to large felines (Helicobacter 
acinonychis Sheeba) revealed profound number of changes resulting in pre-mature stop 
codons [78]. H. pylori appears to lack of mismatch repair function [79]. These findings 
indicate that H. pylori employs efficient strategies to overcome its unusual high 
genomic mutation rate, which could be deleterious. One previous study showed that 
about half of the H. pylori genome could be exchanged during a course of 41 years 
[80]. The study was based on only ten housekeeping genes and extrapolated estimates 
from pairs of sequential isolates at a mean interval of only 1.8 years. 
 
However, it is still largely unknown to what extent and which parts of the genome have 
been changed in the same H. pylori strain after long term colonization in the human 
stomach. These questions can only be answered with confidence after comparisons of 
dozens or even hundreds of the genomes with sequential samples collected decades 
apart. Recent technology advance in high throughput DNA sequencing makes such 
comparisons possible. 
 
To date, only one study has compared sequential H. pylori isolates from the human 
stomach, at the whole genome level [81]. The authors compared four pairs of sequential 
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isolates collected three years apart, among them two pairs included additional isolates 
at 16 years. The four sets of genomes differed by 27 to 232 isolated SNPs and 16 to 441 
imported clusters of polymorphisms resulting from recombination [81]. Since the study 
subjects were from a high risk area and likely harbored mixed strains in their stomachs, 
the authors further compared evolution of a single vaccine strain from a volunteer and 
the results showed no evidence of recombination when the stomach is infected with one 
single strain. However, the time interval of the sampling was only three months. 
 
 
2.4 DNA SEQUENCING  
2.4.1 Shotgun sequencing 
 
 
Figure 2.4 Schematic illustration of shotgun DNA sequencing and De novo assembly. 
 
Because current DNA sequencing method can only sequence short stretches (50 bp to 
1500 bp), long sequences need to be divided into smaller fragments for sequencing, and 
then pieced together (assembled) into the original long fragments (chromosomes) using 
the overlapping parts (Figure 2.4). In de novo assembly, fragments are pieced together 
without any prior sequence information. This process requires relative high sequencing 
depth, such as more than 20 times coverage, to generate good assembly results. Some 
regions in the chromosome may not be sequenced, either by chance due to an 
inadequate sequencing depth, repetitive elements or highly difficult structures 
(homopolymer is difficult for pyro-sequencing, high GC content might be missed by a 
PCR step in the library preparation for Illunima sequencing), and result in gaps (Figure 
2.4).  
 
Mapping refers to alignment of the fragments to a reference genome. The purpose of 
mapping is usually to look for variants.  
 
2.4.2 High-throughput DNA sequencing technology 
Modern DNA sequencing technology has improved dramatically in recent years. One 
of the main differences in current high-throughput DNA sequencing technology as 
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compared with traditional Sanger sequencing is that sample template concentration is 
kept very low to avoid tedious microbial sub-cloning.  
 
Emulsion PCR (emPCR)-based sequencing uses many millions of water-in-oil 
droplets, each of which serves as a separated amplification compartment [82]. Bridge 
PCR-based amplification method uses primers covalently mounted on a glass to 
generate clusters of amplicons [83]. For emPCR, sample library concentration is kept 
so low that the majority of the droplets contain no library, a small proportion contains 
single-molecule libraries and an even smaller proportion contains mixed-molecule 
libraries in a stochastic fashion that follows Poisson distribution. Similarly for bridge-
PCR, sample library concentration is kept low so that most of the amplicon clusters are 
derived from single molecules.  
 
A recent review compared different sequencing platforms in details [84]. The 
technologies, existing and emerging ones are under rapid developments so that the 
information available now will be outdated soon, probably in just a few months. 
Interestingly, the companies often use calendar quarter as the time unit to release new 
products or upgrades. The videos illustrating the technologies are available from the 
websites of these platforms (listed below, with Twitter names). Here I summarize very 
briefly a few key specifications of some platforms. 
 
2.4.2.1 454 sequencing (www.454.com; @454Sequencing; history/upgrades: GS 20, 
GS FLX standard, GS FLX Titanium, GS Junior Titanium [small version 
FLX Titanium], GS FLX+)  
Roche 454 sequencing was the first commercial massively parallel DNA sequencing 
platform available in the market after its first publication in 2005 [82]. Among current 
main sequencing technologies, Roche 454 sequencing is relatively expensive in terms 
of cost per base. The data per run is about 500 Mbp, 1.2 million reads with modal 
length 450 bp (~700 bp for FLX+). Its strength lies in its relative long read length than 
the other common platforms (100 bp in HiSeq2000, 75 bp in SOLiD). Despite its 
relatively high cost, it is still commonly used for applications such as de novo 
sequencing of microorganisms and amplicon sequencing. The technology (pyro-
sequencing) is prone to homopolymer errors (e.g. the amount of lights generated from 6 
adenosines [As] in a stretch is smaller than six times the amount of a single A, and may 
be mistakenly regarded as 5 As) [85]. 
 
2.4.2.2 Illumina sequencing (www.illumina.com; @illuminainfo; history/upgrades: 
Solexa, Genome Analyzer, HiSeq, MiSeq [small version of HiSeq]) 
The Illumina sequencing is currently the leader in the market share. It has the highest 
throughput per run (up to 600 Gbp for HiSeq) among all current platforms. The read 
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length is ~100 bp. The platform is suitable for most applications. The standard Illumina 
library construction involves a PCR step, which is associated with GC content bias 
[86].  
 
2.4.2.3 SOLiD (www.appliedbiosystems.com, @LIFECorporation, 
history/upgrades: SOLiD2, SOLiD3, 5500[xl] SOLiD) 
SOLiD sequencing is the third player in the next-generation sequencing market. Its 
throughput is also high (up to 300 Gbp), and the read length is ~75 bp. This platform 
has the highest sequencing accuracy (> 99.99%), which is important in the clinical 
setting. 
 
2.4.2.4 Ion Torrent – Personal Genome Machine (www.iontorrent.com; 
@iontorrent; upgrades of the chips: 314, 316) 
The IonTorrent sequencing was the first post-light sequencing platform. Its strength lies 
in its fast turnaround time – within one day, as compared with about 2 days for 454 and 
1 - 2 weeks for Illumina and SOLiD. The fast speed makes it particularly suitable for 
pathogen identification. As an example, the microorganism responsible for the recent 
outbreak of EHEC in Europe was quickly sequenced using the Ion Torrent sequencing 
by Beijing Genome Institute, followed by a quick crowd-sourcing annotation of the 
data (https://github.com/ehec-outbreak-crowdsourced/BGI-data-analysis/wiki). The 
relative small size machine is also an advantage for small laboratories or hospitals.  
 
2.4.2.5 Pacific Biosciences (www.pacificbiosciences.com; @PacBio) 
The PacBio sequencing is a single-molecule real-time sequencing (SMRT) platform 
and generates longest reads currently available (> 1000 bp). Despite its low sequencing 
accuracy (currently ~ 91%), the accuracy is constant from the start till the end of a read. 
The accuracy in all other current available platforms are high (> 99%) at the starts of 
reads, but drop as they read toward the ends. The long read length is particularly useful 
for de novo, amplicon and copy number variation sequencings. Another very attractive 
and unique feature is the ability to read epigenetics (methylation) directly – based on 
the slowdowns when the polymerase encounters methylation sites during real-time 
reading [87]. 
 
There are other platforms such as Helicos (the first single-molecule sequencing 
platform) which has relatively short reads (35 bp) and has mainly been used for 
transcriptome sequencing (RNA counts). Complete Genomics has been focused on 
human genome sequencing and only provides sequencing service (samples in, data 
out). Emerging technology such as nanopore might provide a totally different way of 
sequencing. However, each technology has its own strength, and it appears that more 
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and more studies are using more than one platform, such as 454 plus HiSeq, to 
complement each other. 
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3 AIMS 
The overall aim of this thesis was towards identification of molecular risk factors for H. 
pylori-associated stomach cancer. 
 
• To study the associations between the genetic variations in one host gene and H. 
pylori infection, and gastric cancer risk. 
 
• To characterize genomic mutations and recombinations of H. pylori in the time 
frame of its carcinogenic actions, presumably decades in the human stomach. 
 
• To develop methods allowing high-throughput DNA sequencing technology 
using trace amounts of starting material. 
 
• To develop methods for sequencing microbial genomes in decades-preserved 
formalin-fixed and paraffin-embedded gastrointestinal biopsies. 
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4 MATERIALS AND METHODS 
 
4.1 CASE-CONTROL STUDY 
Paper I used a population-based case-control study on gastric cancer conducted in 
Warsaw, Poland between 1994 and 1996 [88]. Cases (n = 464) were patients newly 
diagnosed with histologically confirmed gastric cancer. Controls (n = 480) were 
randomly selected from the computerized population registry and frequency matched to 
the cases by sex and age (± 5 years). Blood samples were obtained from 305 (65.7%) 
cases and 427 (90.0%) controls. Genomic DNA, after uses for previous studies, was 
available from 273 cases and 377 controls.  
 
Serum levels of IgG antibodies against H. pylori whole cell antigens and antibodies 
against CagA were measured using ELISA, as described [89]. 
 
4.2 H. PYLORI CULTURE ISOLATES 
Paper II used H. pylori isolates from patients with dyspepsia who underwent 
gastroscopies in both 1990 and 2010, at Sandvikens, Gälve, Sweden. Frozen biopsies 
taken from the corpus were retrieved for culturing of H. pylori. Random amplified 
polymorphic DNA (RAPD) using primer sets 1283 and 1290 as described previously 
[90] was used to screen for isolates showing consistent patterns between one isolate 
collected in 1990 and two isolates collected in 2010. A total of 21 isolates from 7 
patients were subjected to Roche 454 sequencing. 
 
Paper III used the H. pylori strain HPAG1, previously isolated from a patient diagnosed 
with chronic atrophic gastritis [75].  
 
Paper IV used two frozen biopsies from patients who underwent gastroscopies in 1995 
and were diagnosed with non-cardia gastric cancer, from a previous endoscopy clinic-
based study [91]. At the time of this study, the frozen biopsies were retrieved and used 
for H. pylori culture.  
 
4.3 FORMALIN-FIXED AND PARAFFIN-EMBEDDED (FFPE) BIOPSY 
Paper IV used two FFPE biopsies collected at the same gastroscopy as the frozen 
biopsies described above. These biopsies had been pr severed in ambient temperature 
since 1995. 
 
4.4 LASER CAPTURE MICRODISSECTION 
 
e
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Figure 4.1 Laser capture microdissection (LCM) of H. pylori. 
 
From each of the FFPE biopsy blocks, six sections, each 5 µm thick, were cut with 
disposable and autoclaved microtome blade. The surface section was discarded to 
reduce contamination. The other 5 sections were placed on autoclaved de-ionized warm 
(about 45°C) water. To guide the microdissection of H. pylori on the adjacent de-
paraffinated sections, the second and sixth sections were collected on glass slides for 
immuno-histochemistry staining of H. pylori. The third to fifth sections were collected 
on molecular grade membrane-mounted PALM slides (Carl Zeiss). These sections were 
de-paraffinated and followed by laser capture microdissection (Carl Zeiss PALM 
System, Figure 4.1) of H. pylori, which constituted the two metagenomics H. pylori 
samples in Paper IV. 
 
4.5 DNA SEQUENCING  
Roche 454 Genome Sequencer FLX Titanium platform was used for DNA sequencing 
in Papers II, III and IV. 
 
4.6 BIOINFORMATICS ANALYSES 
De novo assembly and sequence mapping were performed using Newbler, an algorithm 
best accommodating pyrosequencing data and is integrated in the Roche 454 
gsAssembler and gsMapper.  
 
In the analyses of sequence variants, we analyzed only those mapping results that were 
deemed to be of high confidence by the software. The gsMapper application uses a 
combination of flow signal information, quality score information, and difference type 
information to determine if a difference is of High-Confidence. The general rules are i) 
there must be at least 3 non-duplicate reads with the difference, unless the expected 
number (- e option) of reads with the difference is specified, in which case there must 
be 10% of the expected depth having the difference; ii) there must be both forward and 
reverse reads showing the difference, unless there are at least 5 reads with quality 
scores over 20 (< 1% error rate) or 30 (< 0.1% error rate) if the difference involves a 5-
mer or higher;  iii) if the difference is a single-base overcall or undercall, then the reads 
with the difference must form the consensus of the sequenced reads (i.e., at that 
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location, the overall consensus must differ from the reference) and the signal 
distribution of the differing reads must vary from the matching reads (and the number 
of bases in that homopolymer of the reference). 
 
Most sequencing platforms generate sequences with accuracy higher than 99%, but are 
not 100%. Computer algorithms for genome assembly and mapping are not perfect 
either. Even though cautions have been taken to generate ‘High-Confidence’ results, in 
the comparisons of genomes that contain about 1.65 million bases (a very small 
genome as compared with other organisms), the artifacts stem from sequencing and 
computer algorithms might be substantial. To overcome this, a novel self-mapping 
approach was used to reduce errors caused by these artifacts in the analyses of genomic 
evolutions in Paper II. During self-mapping, raw reads were compared with (aligned to) 
their de novo assembled contigs. We applied this self-mapping approach to a previously 
published H. pylori strain V225d [92] that had been sequenced using Roche 454 
sequencing as well. The results showed that there were 22 high-confidence variants 
when comparing V225d raw reads with V225d assembled contigs. These within strain 
variants might arise also from, besides the aforementioned technical errors, potential 
true phenomenon for this highly diverse bacterium. Nevertheless, in whichever case it 
would confound the strain evolution over time. Thus, these variants identified by self-
mapping within the first time isolates in 1990 were subtracted from the variants 
(overtime comparison) identified in the 2010 isolates to identify true changes over time.  
 
The number of variants for strain V225d identified by self-mapping (n = 22) is 
consistent with the number of variants identified in the 1990 isolates in our study (range 
9 to 41, mean 24), except one isolate (ID p539) showing extraordinary high number of 
variants (n = 209). This indicates that the isolates cultivated from this patient’s 1990 
biopsy might contain multiple strains. RAPD patterns for the isolate collected from this 
patient, one in 1990 and two in 2010, were non-distinguishable, indicating that the 
same multiple strains co-existed in one stomach over 20 years. In the analyses of 
genomic changes over time, sequence data from this patient were excluded to ensure 
valid estimations on H. pylori genomic changes over time. 
 
We applied the same cutoff (200 bp) as in a previous study [81] to categorize the 
variants into two groups, namely isolated single nucleotide change (iSNC) and 
clustered single nucleotide change (cSNC). When the variants occurred very close (<= 
200 bp) to each other, they are more likely to be a result of recombination/import rather 
than point mutations. To annotate those sequences subjected to point mutation, 60 bases 
flanking the point mutation were aligned (Standalone NCBI BlastX 2.2.24+ [93]) to the 
eight annotated H. pylori genomes available from GenBank. These strains are 26695, 
J99, HPAG1, Shi470, G27, P12, B38 and B8. Genomes of two other strains PeCan and 
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SJM which were also available but lack of annotation at the time of this writing were 
not included. Both of the sequences in question (60 bases with and without the 
mutation nucleotides from 2010 and 1990 isolates, respectively) were retrieved for the 
alignment and, if hit a coding region, the resulting amino acids were compared to 
identify mutation type (synonymous or non-synonymous). Median and maximum 
import lengths were calculated for each isolate. To annotate imports, the entire import 
sequences were aligned (BlastX) to the eight GenBank genomes. 
 
4.7 STATISTICAL METHODS 
In Paper I, Hardy–Weinberg equilibrium was tested using Pearson’s χ2-test in cancer-
free controls. Odds ratios (ORs) with 95% confidence intervals (95% CIs) derived from 
unconditional logistic regression models were used to assess relative risks. Firth’s 
penalized maximum likelihood estimation was used in case of data separation [94]. 
Haplotypes were inferred with comparison groups (infected vs uninfected, or cancer 
cases vs controls) jointly by an Expectation-Maximization algorithm, and analyzed by a 
“sliding-window” approach with varied window sizes ranging from 2 to 4 tagSNPs 
[95]. The probabilities, inferred from the EM algorithm, of having certain haplotypes 
for each individual were used as weights in a logit binomial model [96].  
 
To account for increased type I errors of multiple testing, statistical significance was 
assessed by empirical P values derived from 10,000 permutations (Paper I) or adjusted 
P values from the Benjamini and Hochberg method (FDR, Paper II). 
 
Generalized estimation equation (GEE) model was applied to account for non-
independency among observations – several haplotypes with different probabilities for 
one individual (Paper I) and the mutations and recombinations observed in replicate H. 
pylori isolates from the same patients (Paper II). 
 
Poisson distribution was used to predict the distribution of DNA molecules in micro-
droplet (Paper III). The probability that there are exactly k DNA molecules on one 
library capture bead (k = 0, 1, 2, ...) is equal to: 
 
 
 
where λ is the input DNA-to-bead ratio. Therefore, the probability of having zero and 
one DNA molecule on one bead is e-λ and λ•e-λ, respectively, and the enrichment 
fraction is 1 - e-λ. 
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The precision of a laboratory assay was evaluated by the mean and standard error of the 
coefficient variation from a serial of triplicate samples (Paper III). 
 
The number of genes being sequenced increases with sequencing depth, but levels off 
at certain point beyond which few new genes are sequenced compared to the amount of 
additional data. In Paper IV, to assess how unique sequences gain with increasing 
sequencing depth, simulations (n = 1000) with replacement was used. Each simulation 
contained a specified number of randomly sampled sequences, increased in steps of 100 
up to the total number of sequences available.  The number of unique sequences for 
each simulation dataset was calculated, as was the average number derived from 1000 
simulation datasets. These average numbers (Y axis) were plotted as a function of the 
sample numbers (X axis). 
 
Data were analyzed using R (http://www.R-project.org/), SAS 9.2 (SAS Institute, Cary, 
NC) and Linux shell scripts. 
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5 RESULTS AND DISCUSSIONS 
 
5.1 STUDY I 
We hypothesized that genetic variation in A4GNT, which could lead to varied 
expression or function of this transferase, may be related to the ability of H. pylori to 
establish colonization, and consequent gastric cancer risk. We tested these hypotheses 
using blood samples from a case-control study conducted in Poland. 
 
All seven tested SNPs were in Hardy-Weinberg equilibrium. SNP rs2622694 
heterozygous genotype AG was associated with a 49% reduced risk of H. pylori 
infection compared with the most common genotype AA (OR 0.51, 95% CI 0.26-1.01). 
A similar magnitude of reduced risk was observed for the homozygous variant 
genotype GG (OR 0.52, 95% CI 0.21-1.31).  For SNP rs397266, the heterozygous 
genotype AG conferred a 68% higher risk of H. pylori infection than the most common 
genotype GG. All carriers (n=29) of the homozygous variant genotype AA had H. 
pylori infection. Armitage trend test revealed a P value of 0.003, which remained 
significant after correction for multiple tests (0.036). In haplotype analysis, among the 
fifteen sliding windows, three (rs2622694-rs397266, rs2246945-rs2622694-rs397266 
and rs329386- rs2246945-rs2622694-rs397266) had haplotype profiles that differed 
between the infected and uninfected groups. These three windows all pointed to a 
significant effect of haplotype at loci rs2622694-rs397266. Compared with the most 
common (G-G) haplotype, haplotype A-A was associated with a significantly higher 
risk of H. pylori infection (OR 2.30, 95% CI 1.35-3.92, global P 0.0019). This 
association remained significant after correction for multiple tests (empirical global P 
value 0.045). 
 
None of the tested SNPs was associated with gastric cancer risk, in both single-locus 
and haplotype analyses.  
 
In vitro studies showed that A4GNT encodes a transferase that helps forming certain 
structure of O-glycans [41]. This glycans can inhibit H. pylori growth by inhibiting the 
biosynthesis of cholesteryl-alpha-D-glucopyranoside, a major H. pylori cell wall 
component [42,43,97]. In contrast to an expected beneficial effect of the A4GNT gene 
product, two small clinical series studies showed up-regulated expression of A4GNT 
mRNA in patients with gastric cancer [98].  One explanation for this discrepancy may 
be the existence of functionally impotent subclasses of the A4GNT-encoded enzyme. 
This is supported by the observation that the expression of the A4GNT enzyme, but not 
of the A4GNalpha1-4Galbeta-R (a mucous gland specific mucin specific glycan that 
suppresses H. pylori growth), was up-regulated amongst patients with H. pylori gastritis 
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and decreased to normal level after H. pylori eradication [39]. The up-regulation of 
A4GNT enzyme accompanied by unchanged amount of A4GNalpha1-4Galbeta-R 
suggests that there exist subclasses of A4GNT with little or no transferase activity. 
Hosts with up-regulated expression of non-functional A4GNT subclasses would be less 
capable of preventing H. pylori from establishing colonization and, consequently, could 
have more severe clinical outcomes, such as gastric cancer [98]. 
 
Examining into the amino acid sequence of A4GNT [40] that had been used in the 
previous in vitro studies [42,43], in which the A4GNT, producing a glycan suppressing 
H. pylori growth, had an alanine at position 218 (corresponding to a C allele at 
rs2246945), consistent with our finding that the C allele rs2246945 was associated with 
reduced risk for H. pylori infection. 
 
In the study, A4GNT variation was associated with H. pylori seropositivity but was not 
associated with overall gastric cancer risk. The proportion of the risk haplotype A-A at 
loci rs2622694-rs397266 was 17% among the uninfected group in this study. Such a 
relatively low prevalence requires a larger sample-size study to examine for moderate 
or modest effects of A4GNT on gastric cancer risk. 
 
 
5.2 STUDY II 
To characterize genomic mutations and recombinations of H. pylori in the time frame 
of its carcinogenic actions, presumably decades in the human stomach, we sequenced 
whole genome of 7 pairs of sequential H. pylori isolates from 7 patients, with 1 isolate 
collected in 1990 and 2 replicates collected in 2010 for each patient, totally 21 isolates.  
 
Number of point mutation and import over 20 years 
Point mutations and imports scattered across the genomes. The number of point 
mutations over 20 years was on average 261 (range 70 to 488, Table 1). These 
mutations affected mostly outer membrane encoding genes (hopP/sabA, hopZ, 
hopS/babA, hopK, hopL, hopU/babC), and genes involving in chemotaxis and flagellar 
biosynthesis, tRNA synthetase, cagPAI, vacA, restriction and modification system and 
fucosyl- and glyco-transferase. The mean number of imports per isolate was 45 (range 
18 to 92). The median length of imports ranged from 49 to 151 bp for all the 12 
isolates, with max length of import 2,241 bp observed in one isolate. The imports had 
been mostly observed in genes having unknown functions, followed by genes encoding 
outer membrane proteins, cagPAI, fucosyl- and glyco-transferase, chemotaxis and 
flagellar biosynthesis, vacA, replicase, restriction and modification system.  
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Isolate 
Number 
of 
variants 
present 
in 1990 
Total number 
of variants 
after exclusion 
of variants 
present in 1990 
Isolated single nucleotide change 
(iSNC), n   
Clustered single 
nucleotide change 
(cSNC), n 
Total Synonymous 
Non- 
synonym
ous 
Non-coding 
/intergenic   n 
length, 
median 
length, 
max 
p3:1 3 325 203 144 16 43 28 107 783 
p3:2 3 327 198 138 16 44 29 92 535 
p64:1 14 499 324 235 15 74   36 121 898 
p64:2 16 503 328 232 17 79   35 151 898 
p70:1 22 799 488 399 25 64 92 87 756 
p70:2 28 422 323 254 19 50 31 63 417 
p121:1 3 700 235 169 25 41   67 95 1031 
p121:2 5 740 241 175 20 46   76 88 1031 
p138:1 8 556 290 218 25 47 39 114 624 
p138:2 7 184 70 49 3 18 18 121 589 
p230:1 5 583 207 149 18 40   43 92 2119 
p230:2 6 635 220 153 22 45   51 49 2241 
p539:1 96 277 162 116 11 35 35 106 522 
p539:2 73 188 80 47 9 24   27 82 546 
 
Table 1.  Number of variants in the isolates sampled in 2010 (two isolates :1 and :2) as compared with 
the isolate sampled in 1990, with mutation types, after exclusion of self-mapping variants already present 
in 1990 
 
Function category analysis revealed that point mutation and import (recombination) 
occurred more often in un-annotated genes, 40% and 62%, respectively, as compared 
with about 29% un-annotated genes in the eight H. pylori genomes currently available 
in GenBank (Figure 5.1). Among annotated genes, point mutations were 
overrepresented in the function categories N (cell motility), K (transcription), D (cell 
cycle control, cell division, chromosome partitioning) and P (inorganic ion transport 
and metabolism), all with statistical significance. Although point mutations occurred in 
high frequency in category M (cell wall/membrane), its difference in relative proportion 
with the eight GenBank genomes did not reach statistical significance. Among 
annotated genes, imports were highly overrepresented in the function category N (cell 
motility) with statistically significance as compared with the GenBank reference 
genomes. Imports also occurred in high frequency in the category U (intracellular 
trafficking), but was not statistically significant. 
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Figure 5.1 Percentage of annotated genes (a) and function categories (b) among the 8 GenBank H. pylori 
genomes (Hp8), the isolated single nucleotide change (iSNC) and clustered SNC (cSNC) identified in the 
12 isolates over 20 years. Horizontal bars indicate standard errors.  
 
The analysis of clusters of orthologous group (COG) showed that point mutations 
frequently affected COG5651 (vacuolating cytotoxin [vacA]-like protein), COG0840 
(methyl-accepting chemotaxis protein), COG0610 (type I site-specific restriction-
modification system, R [restriction] subunit), COG0086 (DNA-directed RNA 
polymerase, beta subunit), COG1674 (DNA segregation ATPase FtsK/SpoIIIE) and 
COG1538 (nickel cobalt outer membrane efflux protein), with their relative proportions 
statistically significantly higher than those in the eight GenBank reference genomes. 
For the import group, overrepresented COGs were COG2948 (DNA transformation 
competence protein ComB10 / VirB10 components / type IV secretion system / cagY, P 
= 0.02) and those without statistical significance COG5651 (P = 0.12), COG3306 
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(lipopolysaccharide biosynthesis protein, P = 0.054), COG5527 (replication initiation 
protein A, P = 0.37) and COG0840 (P = 0.22)  
 
Genomic fusion was a frequent event in H. pylori and about 8 fusions per strain had 
accumulated after 20-year infection in the human stomach. These fusions mostly 
affected outer membrane genes. About two events of duplications, particularly tandem 
repeat, had accumulated over 20 years per strain. These duplications occurred mostly in 
lipopolysaccharide related genes and DNA transformation competence protein 
ComB10, VirB10 components, and type IV secretion system (cagY). Deletion, insertion 
and substitution were relatively rare events and occurred in sequences with unknown 
functions. 
 
We observed that 85% of single nucleotide substitutions belonged to transition and 
15% to transversion. Mutation sequence context analysis revealed that an A or G 
nucleotide at the 3’ of dinucleotide GC, namely the third nucleotide in GCA or GCG, 
was subjected to mutation more often than other sequence context (Figure 5.2). 
 
 
Figure 5.2. Percentages of single nucleotide subjected to mutation (dotted in red), among all isolated 
single nucleotide changes (iSNCs) occurring in a H. pylori isolate after 20-year colonization in the human 
stomach, in the context of different dinucleotide. The most frequent mutation site was an A or G at the 3’ 
of dinucleotide GC (a) or a T or C at the 5’ of dinucleotide GC (b), or a G the 5’ of dinucleotide CT (b). 
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We observed that extensive mutations had occurred in H. pylori over 20 years, further 
supporting previous notion that H. pylori is one of the most diverse bacteria. In line 
with mutations observed in many bacteria, transition, rather than transversion, is the 
major form of single nucleotide substitution in H. pylori. Mutation frequency is 
associated with specific sequence context that a nucleotide A or G is a hot mutation 
spot if downstream to the dinucleotide GC.  
 
In the stomachs infected with single H. pylori strains, we observed also frequent 
clustered nucleotide changes which are likely representing recombinations. A previous 
study comparing a single strain vaccine indicated no recombination [81]. However, it 
was only 3 months apart for the isolates in comparison. The numbers of recombination 
over 20 years after single strain colonization we observed (18 - 92) were smaller than 
the numbers of recombination observed in the previous study (16 - 441). This might be 
due to colonization of mixed strains in the previous study, which was conducted in a 
high H. pylori prevalent area [81]. However, the sources of homologue recombination 
for these single strains are unknown. Transient H. pylori or homologue genes in other 
gut microbe might contribute to the recombination. This hypothesis however requires 
further investigations. 
 
 
5.3 STUDY III 
Current high-throughput DNA sequencing technologies generally require substantial 
amounts of starting material such as more than 100 nanogram of double-stranded DNA. 
However, clinical samples are often precious and of low amounts. We designed double-
stranded library protocols (simplified AB and Y, Figure 5.3) for the Roche 454 
platform to avoid the yield-reducing steps associated with single-stranded library 
preparation. We designed a highly sensitive Taqman MGB-probe based quantitative 
PCR method for library quantification (Figure 5.4). 
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Figure 5.3 Schematic illustrations of three types of library construction. 
 
Our Taqman MGB-probe-based qPCR facilitates quantification of minute amounts of 
sequencing library, and quantify only those library molecules that are functional. We 
demonstrated that the distribution of DNA on beads after emulsification follows a 
Poisson distribution, which enabled us to predict enrichment percentage, a key index 
for successful sequencing. The ability to avoid labor-intensive and costly titration assay 
in the standard protocol by combining Poison statistics and our qPCR setup was 
evaluated retrospectively using previously sequenced FLX Standard libraries and 
prospectively using newly generated libraries. There was no significant difference 
between observed and predicted enrichment percentages (paired t-test P = 0.92). The 
precision and reproducibility of this qPCR assay (coefficient variation 9.5%) is at least 
as good as a digital-qPCR based on a microfluidic system (coefficient variation 11.8%) 
[99], which is expensive and not generally available in ordinary laboratories.  
 
 
Figure 5.4 Library quantification by qPCR 
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With the Taqman-MGB probe-based qPCR and Poisson distribution, we were able to 
avoid the costly and labor-intensive titration assay. Using only one nanogram of 
fragmented DNA, we prepared enough library (1.15 million amplifiable AB library 
molecules and 53.6 million Y library molecules) for Roche 454 Titanium sequencing 
without the need for template pre-amplification by various means of whole genome 
amplification [100,101]. However, it should be acknowledged that some factors 
causing sample loss remained, such as fragmentation of genomic DNA, low efficiency 
of ligation and a limited recovery at the enzymatic reaction clean-up [102]. This was 
clearly shown by a much higher yield of Y library (sticky-end ligation) than AB library 
(blunt-end ligation and two additional reaction clean-up steps).  
 
Library quantification by qPCR has been earlier proposed to overcome the lower 
detection limits of conventional methods [99,103]. We used a Taqman MGB-probe to 
take advantage of the fact that Taqman MGB-probe provides significantly higher 
sensitivity, specificity and reproducibility than conventional Taqman probes [104]. 
 
Poisson distribution demonstrates that imprecise library quantifications within two-fold 
over- or under-estimations will all give satisfactory results when DNA-to-bead ratio is 
low. In contrast, the same level of inaccuracy will lead to undesired results when DNA-
to-bead ratio is high. In a previous study, a linear regression model was used to 
correlate input DNA-to-bead ratio with enrichment percentage [105]. The linear 
regression method may suffer from limitations of a positive intercept (meaning that 
there will be enriched beads even with no input library) and unlimited enrichment 
percentage (can be higher than 100% when DNA amount increases). However, when 
the input DNA-to-bead ratio is low, prediction from a linear regression approaches that 
from a Poisson distribution and is then acceptable. 
 
 
5.4 STUDY IV 
To be able to sequence metagenomic profiles of H. pylori from old FFPE samples, we 
used laser capture microdissection (LCM) for physical separation of H. pylori (Figure 
4.1), followed by a limited number of cycles of DNA pre-amplification, the improved 
DNA library construction method for 454 sequencing from Paper III, and customized 
barcoded Y adapters (Zheng et al, Nature Protocols, in press). 
 
Higher identity was observed when aligning FFPE metagenomic samples with the 
culture samples from the same hosts (~ 96.4%) than with the reference genomes or with 
the culture sample of the other patients (~ 92.5%, Figure 5.5). This demonstrates that 
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the metagenomic profile of H. pylori dissected from 15 year old FFPE sections 
faithfully represents the H. pylori populations in its host.  
 
 
* Strains HPAG1, G27, P12, B8 and PeCan1 carry plasmids.  
Figure 5.5 Alignment identity, length and number of reads of two FFPE samples against each of the ten 
GenBank H. pylori reference genomes and the culture samples of the two patients, respectively 
 
When aligning culture raw sequences with culture assembled contigs (self-mapping) 
from the same patient, the identity was about 98.7%. However, higher than 99% 
identity is expected when the same H. pylori strain is compared using 454 sequencing 
and the software gsMapper, as we have shown previously [106]. The lower self-
mapping identity suggests the presence of quasispecies in the isolate sweeps. The 
further lower identity (~ 2.3% lower) when comparing FFPE reads with culture 
assembled contigs may be due to error prone translesion synthesis during PCR using 
formalin-fixed DNA [107]. However, given an estimated translesion synthesis error 
rate of only 0.1% per base [107], other conceivable explanations might be i) a patchy 
distribution of H. pylori in the stomach leading to different strains of H. pylori being 
sampled in the FFPE biopsy and in the culture biopsy; ii) the existence of viable but 
nonculturable coccoid and/or degenerative forms [108,109] of H. pylori in vivo which 
could only be sequenced with metagenomic methods. 
 
An alternative to microdissection may be a hybridization-based method, which could 
be used for enrichment-and-sequencing or for direct detection. This approach has been 
widely used, e.g. for exon sequencing. However, hybridization methods rely on current 
and thus probably incomplete information on the genomic makeup of the studied 
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organism, which may be a limitation in the enrichment of highly diverse microbial 
genomes. Also, hybridization relies on good sequence matching and good hybridization 
conditions (buffer, temperature, time, etc.) to minimize false hybridizations and missed 
targets.  
 
Our exploration of sequences common to FFPE and culture in the same patient but not 
aligning with the comparably large selection of reference genomes demonstrated that 
even in an imaginary perfect hybridization with probes covering the entire genome of 
all ten reference strains, some true but highly variant  H. pylori sequences would still be 
missed. The omission of true H. pylori reads is not surprising as H. pylori is one of the 
most diverse bacteria [70]. One question that might arise concerns how to identify these 
missed true sequences when, in reality, re-cultures are unavailable in most of the cases. 
By using our proposed metagenomic approach, functional genes displaying significant 
difference between cases and controls can be determined using e.g. BLASTx against 
the “nr” database followed by comparisons of their frequencies in the two groups, 
without the need for closely matching reference genomes. 
 
The amount of input DNA required in subsequent steps is also critical for the choice of 
enrichment method. The three commercial hybridization-based methods all require 
input DNA quantities above one microgram [110], sometimes necessitating pre-
amplification. In the previous study using microdissection to analyze microbes from 
fresh colon biopsies [111], about three nanogram of DNA was dissected from ten 0.8-
µm thick sections and was amplified by a multiple displacement amplification method, 
which could have been unnecessary if the library preparation protocol had been 
adjusted for nanogram input DNA with the capability to yield tens of millions of reads. 
Our DNA yield was much less (not detectable by a fluorometry method) due to 
moderate H. pylori density, thinner sections, and degraded DNA and therefore still 
requires pre-amplification. Whole genome amplification is liable to bias, varying with 
the amplification method [101], with the multiple displacement amplification method 
giving less bias than others. However, as multiple displacement amplification requires 
fragment longer than 500 bp (http://www.qiagen.com/products/repli-
gffpekit.aspx#Tabs=t1, last accessed June 11th, 2011), its application on decade-
preserved FFPE biopsies is limited. We therefore applied a PCR-based method and 
amplified for 14 cycles (instead of recommended 25 cycles) to reduce bias. GC content 
is the most established risk factor for amplification bias in PCR-based methods [101]. 
We observed similar GC contents in the amplified and sequenced H. pylori reads (40% 
and 41%) as compared with the reference genomes (~39%). Further, the fairly evenly 
distributed alignment of amplified FFPE H. pylori sequences to the reference H. pylori 
genome demonstrated that the amplification bias was minor, although not totally 
absent. 
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One important limitation of LCM is that it is a labor intensive task and thus may 
hamper its use in large scale studies. However, it needs to be balanced, among other 
considerations, between the amount of work required for LCM and the amount of 
compromised results acceptable from a quick and prior knowledge-dependent 
hybridization approach. The balance will shift towards in favor of the latter if the 
samples are not very precious and are widely available. Ultimately, if one would study 
different H. pylori located in different areas of one biopsy, such as those attached to the 
epithelium from those able to penetrate deep in the gastric gland and interacting with 
surrounding stem cells, it may be only possible to study with a physical separation 
approach. 
 
In all, physical separation through microdissection followed by sequencing provides an 
appealing alternative to commercial hybridization-based methods when microbial DNA 
needs to be separated from host, with an additional advantage of being able to capture novel 
and highly variant genes. Application of this method on FFPE material from the distant past 
might hopefully unveil markers of potential carcinogens in H. pylori strains colonizing the 
stomach before irreversible damage has occurred, and thus pave the way for targeted 
chemoprevention. 
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6 GENERAL DISCUSSIONS 
 
6.1 ON EPIDEMIOLOGICAL ISSUES 
Epidemiologic experiments are often limited by ethics and constrains in time, cost and 
compliance of individuals. For example, a randomized, placebo-controlled, field trial of 
H. pylori eradication among 1630 healthy carriers of H. pylori from a high risk area, 
Fujian Province, China, recruited in July 1994 and followed up until January 2002 had 
resulted in 7 incident cases of gastric cancer in the eradication arm and 11 in the 
placebo arm [64]. The size of the study, about 11,000 person-years in total, was too 
small to adequately assess the effect. Another trial involved 3,365 adults (Linqu, 
Shandong, China, also a high risk area) with 1,142 individuals randomized to receive 
H. pylori eradication, showed a significant improvement in precancerous gastric lesions 
after eradication, however there was still lack of statistical power to conclude its effect 
on gastric cancer [63]. 
 
Observational approach has been the main tool for epidemiologists to observe what 
occur in the natural experiments. In ecologic studies, the units of observation are groups 
of people and are often hypothesis generating, followed by further investigations. For 
example, the observations on the association between the prevalence of H. pylori 
infection and the prevalence of gastrointestinal diseases in different areas opened 
questions for later studies [112,113]. 
 
In a cohort study, exposure information of all subjects in a source population is 
collected first, and then followed up over time to ascertain disease incidence. In a case-
control study, conversely, outcome status (case/control) is identified first, followed by 
assessment of their exposure history. Nested case-control study is an elegant design 
having the advantages of both cohort study and case-control study, for example, a case-
control study on stomach cancer nested within a defined FFPE biopsy cohort. Since 
stomach cancer is a rare disease even among a group of subjects who undergo 
gastroscopy, case-control design allows quick recruitment of hundreds of cancer 
biopsies. Because the biopsies had already been incidentally collected before the 
outcome disease, a nested case-control study design can control for reversed causality 
which exists in a conventional case-control design. For example, in the study of 
carcinogenic factors in related to H. pylori infection, the H. pylori strains collected at 
the time of cancer diagnosis may have adapted to the altered stomach environment in 
the cancer patients, rather than the original ones that responsible for the gastric 
carcinogenesis. This reversed causality occurs due to two preconditions: 1) H. pylori 
genome has rapid genomic mutation and recombination rates and 2) the incubation time 
for gastric cancer is long enough to accumulate genomic changes in H. pylori. 
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Selection bias causes invalid results in both case-control and cohort studies. In case-
control study, selection bias can occur if the controls are not representative of the 
population where cases arise. In Paper I, 79% of eligible controls donated blood. The 
final controls included in the study might have been more likely to be H. pylori-
infected than those persons (21%) who refused to donate blood, due to probable 
symptoms caused by H. pylori infection. This would lead to an underestimated 
association between H. pylori infection and gastric cancer. For our study on the 
association between genetic polymorphisms in A4GnT and gastric cancer, where H. 
pylori infection is supposed to be a mediator, if the aforementioned selection bias had 
existed, the associations would have been underestimated. However, this would not 
affect our study on the association between A4GnT polymorphisms and H. pylori 
infection among controls. In a cohort study, selection bias can also occur such as loss of 
follow-up. For example, H. pylori infected individuals may die of cardiovascular 
diseases (competing risk) on the way of gastric cancer development. If the probability 
of dying of these diseases among non-infected individuals is lower than that of infected 
group, namely an association between H. pylori infection and cardiovascular diseases, 
the relative risk of H. pylori infection on gastric cancer would be biased towards 0 
(although unlikely to across the value 1, from a risk factor to a protective factor, it is 
theoretically possible if the competing risk is strong enough). 
 
Information bias (misclassification) might exist in Paper I if genotyping and serology 
assays were incorrect. If misclassification of exposures is differential between cases 
and controls, the association can either be over- or underestimated. This could have 
happened if the case and control samples were assayed in different batches. Non-
differential misclassification of a dichotomous exposure would bias the association 
towards null. For an exposure having three or more levels, non-differential 
misclassification could lead either under- or over-estimation. However, here is a bit of 
‘unfair’ to claim the misclassification as non-differential, as the comparisons were 
made between two levels (e.g. level 2 vs level 1, and level 3 vs level 1), whereas the 
non-differential misclassification pertains to all levels (which from the perspective of 
the two levels involved is indeed differential). In Paper I, if the serology exposures 
(dichotomous) were misclassified differentially among cases and controls, for example 
more false-negative of H. pylori infection in the cases (due to disease-associated low 
abundance of anti-H. pylori antibodies, which were lower than the detection limit of the 
ELISA assay) than in controls, a true positive association between H. pylori and gastric 
cancer would be biased towards null. Our study of the association between A4GnT 
polymorphisms and H. pylori infection was restricted among controls. 
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In epidemiological studies, often times, researchers are looking for associations that are 
causal. Non-causal associations are also useful such as in the search for biomarkers to 
identify cases. Causal associations are useful to prevent diseases. However, conversions 
of causal factors might not necessarily reduce disease risk – it might be already too late. 
One example is that H. pylori eradication among individuals having advanced 
precancerous gastric lesions showed no benefit in terms of preventing the development 
of gastric cancer, whereas the eradiation among relative healthier (gastritis) individuals 
helps [64]. 
 
Confounding – a confusion of effects [114]. The association between yellow fingers 
and lung cancer is not causal because of confounding effect by smoking. The theory of 
directed acyclic graph (DAG) was originally developed in the setting of artificial 
intelligence [115] and later in epidemiologic setting [116,117]. A modified DAG was 
used in an attempt to address clinical problems [118]. This approach has helped to 
adjust for confounding, but relies on comprehensive knowledge about study variables 
involved. As compared with the complex of human body, not to mention the even more 
complex social behavior, our knowledge in biomedicine is very limited. It is often 
unclear whether exposure A is yellow fingers and exposure B is smoking. Thus, DAG 
might not be a practically useful approach in clinical setting. A non-knowledge based 
approach, i.e. randomization, will be an effective way to address this issue. 
 
For nested case-control study of rare diseases, there are usually enough eligible controls 
to sample from. In incidence density sampling, a sampling set (risk-set) contains one 
case and a set of controls who were free of the diseases at the time of the diagnosis of 
the index case, with some additional matching factors being the same as those in the 
index case, such as age, gender and geography area of residence. Randomization is then 
applied to select the controls for the index case. Occasionally, one control may be 
eligible for different cases at different time points. It is also possible that one individual 
may be a control for another individual and later become a case. Some randomization 
algorithm might specifically avoid these to happen. However, this avoiding actually 
creates bias; for example, resulting in a group of ‘superman’ among controls, though 
the magnitude of bias may be small.  
 
Residual confounding might affect the precision of estimates. For example, when age is 
categorized into < 50, 50 – 60 and > 60, all values in a group is treated as the same. 
However, we know that 50 and 60 years do differ substantially. For a continuous 
variable, the difference of every unit is treated equally. In Paper I, the Armetage trend 
test assigns value 0, 1, 2 to homozygous common allele, heterozygous, and 
homozygous rare allele genotypes, respectively. As a consequence, the effect of 
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homozygous rare is assumed to be the square that of heterozygous, which might not be 
the case and result in imprecise estimate. 
 
 
6.2 ON MULTIPLE TESTS CORRECTION 
Two types of errors can occur in a statistical test, i.e. to reject the null hypothesis when 
it is true (type I error) or accept the null hypothesis when it is false (type II error). A 
statistical significance level 0.05 per hypothesis is commonly used as the acceptance 
level of type I error (false positive). As the number of tests available for one hypothesis 
increases, the chance of false positive for the hypothesis under study increases. Several 
common methods exist for controlling false positive including Bonferroni adjustment, 
permutation, and false discovery rate (FDR).  
 
Bonferroni adjustment uses a significance level 0.05 /n, where ‘n’ is the number of tests 
performed. The underlying assumption is that all the tests are completely independent. 
However, the variables such as SNPs under investigation, for one hypothesis, are often 
times correlated to some extent. Thus, Bonferroni adjustment is too stringent and 
resulting in a high false negative.  
 
In contrast, the permutation method preserves the correlations of the tested variables, as 
it only shuffle the dependent variable in a dataset. For the null hypothesis, the 
dependent variable (case/control) is not associated with the independent variables 
(exposures). Thus, the probability of getting a P value as extreme as the one observed 
in the actual data can be empirically calculated in a large number of permutation 
datasets. For each permutation dataset, a set of multiple tests were performed and the 
minimum P value was recorded. It is in this set-wise manner, the statistical significance 
is maintained at the hypothesis-wise level. The permutation method is the most 
accurate method for controlling multiple tests, but suffers from computational 
constrains when the number of tests is large, and become impossible to perform in the 
omics era. Figure 6.1 is an example of permutation for the haplotype analysis, which 
was part of the analyses in Paper I. It took 17 hours (from 20Feb09 to 21Feb09) to run 
logit binomial model, with sandwich covariance, on 10,000 permutations of a small 
dataset (273 cases and 377 controls) for 15 haplotype sliding windows using SAS 9.2, 
run in batch mode, on a desktop PC with duo CPUs, 4 G RAM (the speed was 
comparable with a Unix server at my department). And, before running the 
permutations, the efficiency of the program was already improved, for about 10 times 
faster, from my first draft of the program. 
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…from the 2nd round, part of log information is turned off (warnings are still on). 
 
 
 
…the process continues until all the 15 sliding windows were completed. 
 
 
 
Figure 6.1 After initial code efficiency improvement, it took 17 hours (from 20Feb09 to 21Feb09) to run 
permutation for the analysis for a small study. 
 
In a list of declared statistical significant tests (rejected null hypotheses), FDR controls 
the expected proportion of false positive (incorrectly rejected null hypotheses) [119]. 
The FDR method deals with only raw P values so that computational resource is not a 
concern. Although not as accurate as permutation, FDR is the approach of choice for 
large number of tests in the omics era. 
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6.3 SNPS IN A DIPLOID CELL 
 
Figure 6.2 Identical SNPs data but different haplotypes in diploid cells. 
 
Single nucleotide polymorphism (SNP) represents genetic information at a single point on a 
chromosome. For monoploid cell such as most bacteria, genomic variation is wholly 
represented by SNPs, except some tandem repeats or copy number variations. As the ploidy 
increases (diploid, triploid, tetraploid…), genomic variations become more and more 
complex and more difficult to be represented by SNPs. Human are diploid, meaning that a 
human somatic cell contains two complete haploid sets (sperm and egg gamete). One SNP 
corresponding to two nucleotides, one inherited from mother and the other from father. Two 
or more SNPs contain nucleotides in a ‘non-connected’ form. For example, John’s genetic 
blueprint at locus 1 is A/G and locus 2 G/C (Figure 6.2). Reza has same SNPs data as John at 
the two loci. However, their genetic makeups at these two loci are clearly different. In 
molecular biology, genetic information is read through in a stretch (haplotype) by 
polymerases. The difference in John and Reza’s haplotypes at these two loci could result in 
different amino acids being translated, different levels of mRNA expressions in their 
downstream region or difference in on/off status of a downstream gene, despite identical 
SNPs data. 
 
As the number of involving SNPs increases, the possibility of different haplotypes increases 
rapidly, while the actual number remains two. For example, if a haplotype spans 20 
heterozygous loci, over one million of haplotypes (2^20 = 1,048,576) could theoretically be 
constructed. When high-density oligonucleotides arrays were used to genotype hundreds of 
thousands of SNPs across the entire genome, genome wide association study (GWAS) 
became possible. Various statistically methods have been developed to infer (guess) most 
likely haplotypes, for example, based on maximum-likelihood estimate. The author’s 
computer can only calculate possible combinations of haplotypes up to 1023 heterozygous 
loci (2^1023 = 9E307; 2^1024 = infinite). Although it might never involve so many loci in a 
stretch for a certain biology process, 20 loci can already result in 1 million possible guesses 
of haplotypes and lead to extensive computation in the data analysis for a case-control study 
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involving hundreds of subjects. Statistical method can be improved for easier computation – 
a set of SNPs can be partitioned into small units first and recombined subsequently. 
However, even for haplotypes spans only 20 heterozygous loci, infer 2 true haplotypes (or 
let’s not so picky and allow 20 ‘representative’ haplotypes) from 1 million possibilities, to 
me, is kind of mission impossible. Thus, statistics is unlikely to be able to faithfully restore a 
stretch DNA sequence from dozens of SNPs, without losing critical biological information. 
Although haplotypes at certain significant regions identified by SNPs may be obtained with 
confidence by re-sequencing, haplotypes that are informative but were not picked up by 
SNPs in the first place are lost. The loss of critical biological information is likely to be 
worse for more complex diseases, such as cancers. 
 
 
6.4 GENOMIC ENRICHMENT 
DNA enrichment is useful for hypothesis-driven studies to zoom in certain genomic 
regions of interest (or genomes of interest such as in Paper IV) and allows for more 
samples to be sequenced or the same amount of samples with much higher sequencing 
depths (for identifying rare key mutations in a bulk of majority benign tissue cells).  
 
6.4.1 Sensitivity 
Sensitivity – the percentage of target being sequenced over total length of a target. It 
increases with increasing sequencing depth and levels off at a certain point beyond 
which little is gained compared to the amount of additional data. The sequencing cost 
can be reduced by reducing sequencing depth to the level where the sequencing depth 
versus gene yield curve levels off and the marginal cost per additional gene becomes 
prohibitive. Thus, more samples, such as in an epidemiological setting, could be 
sequenced with the same budgetary constraint. The sequencing redundancy in three 
commercial hybridization-based methods, to achieve a similar level of target (67%, the 
approximate level-off point for all the three methods), was 57 to 171 times [110]. 
Foreseeably, sequencing redundancy is rapidly becoming less of a concern as the 
sequencing cost continues to fall. 
 
6.4.2 Specificity 
Specificity – the fraction of sequenced reads that aligned to the region of interest. For 
the three commercial methods, the number of reads that aligned to the region of interest 
over total number of reads ranged from 52% to 59% [110]. In Paper IV, about 5% of 
DNA fragments that we dissected from the FFPE sections could be mapped to H. 
pylori, and the rest was mostly human and unknown. Considering the size of the human 
genome (~ 3.3 billion base pairs) and that of H. pylori (~ 1.65 million base pairs), the 
5% being H. pylori reflected a contamination of 1 human cell in more than one hundred 
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H. pylori cells, demonstrating a significant enrichment of H. pylori. The human DNA 
observed in our dissected material might partly derive from tissue cell disruption during 
long-term storage of the biopsy at the ambient temperature and mechanical trauma 
during sectioning. 
 
New targets enrichment method such as rolling cycle amplification-based multiple 
displacement amplification has been shown to achieve high sensitivity and specificity, both 
are higher than 95% [120]. Further studies are needed to evaluate its performance when 
being applied on highly diverse microbial genomes, as prior knowledge of the targets is still 
required to design probes. 
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7 CONCLUSIONS 
 
• Genetic variants of A4GNT are related to H. pylori infection, but not to gastric 
cancer risk. 
 
• In the stomach infected with a single H. pylori strain, extensive mutations and 
recombinations can accumulate in H. pylori after 20 years. High recombination 
rates in genes involving in intracellular trafficking and mutations in the cell 
defensive and motility systems imply selection of H. pylori via horizontal gene 
transfer for advantageous genes during long term colonization in the stomach. 
 
• Current high-throughput DNA sequencing technology can be applied on trace 
amount of starting materials by using advanced DNA library construction and 
quantification method. 
 
• Archived FFPE gastric biopsies can be used to sequence H. pylori genome for 
longitudinal study of H. pylori metagenomics and stomach cancer risk. 
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8 FUTURE PERSPECTIVE 
 
8.1 H. PYLORI AND GASTRIC CANCER 
The upward trend of gastric corpus cancer observed in the US warrants similar 
investigations in other parts of the world. After decades of antibiotic action by human, 
H. pylori might start to react. The phenotypes of H. pylori currently circulating in the 
world might be different from those circulating decades ago. Latency period might 
need to be bear in mind when interpreting the two secular trends in one picture. 
 
A very intriguing question is why some H. pylori infections result in gastric cancer, 
whereas some others result in a condition (duodenal ulcer) that prevents gastric cancer 
– a phenomenon pertains to both Eastern (high risk area) and Western (low risk area) 
countries. Whole genome sequencing of the bacteria to compare isolates from duodenal 
ulcer patients with isolates from pre-cancer patients may provide a clue. A case-control 
study using deep sequencing to compare targeted host genetic loci involving in H. 
pylori adherence and antigen presentation may also help, as H. pylori tend to play 
critical roles at early stages, where the destiny of the infection might have been shaped. 
 
H. pylori is acquired in childhood and causes both diffuse type and intestinal type of 
stomach cancers, but at different speed in that diffuse type appears earlier (age ~50) and 
intestinal type comes in elderly (age 65+). Identification of the determinants of the 
speed would not only be an interest for cancer etiology, but would also facilitate 
estimation of stomach cancer burden based on disability-adjusted life year (DALY). 
 
Epigenetic changes in the stomach tissue imprinted by H. pylori would be important 
molecular events in H. pylori related carcinogenesis to be revealed. 
 
Availability of non-invasive detection methods of H. pylori infection and antibiotic 
resistances rapid and simple enough for a clinician in the countryside to prescribe the 
right antibiotics to patients (if eradications are warranted) would be wonderful. 
Vaccination of H. pylori during childhood, if successful after evaluation of efficacy and 
long-term safety, would be a very effective approach to reduce stomach cancer burden. 
 
 
8.2 MOLECULAR EPIDEMIOLOGY 
Molecular epidemiology would be more attractive if the studies involve small numbers of 
subjects rather than going towards gigantic studies. Currently, molecular epidemiologic 
studies appear to be shifting towards larger and larger sample sizes such as thousands or 
even tens of thousands of cases and controls. This is due to, at least in part, two reasons. 
First, the resolution for differentiating diseases under study is still low. For example, we have 
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been able to divide stomach cancers based on anatomical site and histology. However, a 
defined cancer based on these two criteria still consists of a dynamic bulk of cells having 
different features, and with different proportions at different time points. Second, we cannot 
yet measure molecules (the exposures) well enough. Measurements at the single-cell 
haplotype, single-cell epigenetic haplotype or single-cell transcriptome level would facilitate 
the unveiling of the fundamental processes of decoding genetic information. 
 
Technology drives biomedicine research. Pathologists use microscope and can differentiate 
tumors into subtypes, for example, adenocarcinoma from squamous cell carcinoma of the 
esophagus. With the assistance of immunohistochemistry staining, the resolution can be 
improved to differentiate, for example, estrogen receptor positive from progesterone receptor 
positive breast cancers. Oligonucleotides micro-array enables us to look at the whole genome 
single nucleotides polymorphisms. Next-generation sequencing is a big step towards 
decoding the fundamental process of molecular biology. Recently, technique for whole-
genome single cell haplotyping has been developed [121]. Foreseeably, technique for whole-
genome single cell epigenetic haplotyping will be available soon. 
 
Molecular classification of tumors facilitates stratification of cancer patients to receive the 
‘smart’ drug in personalized medicine [122]. Identification of biomarkers in patients with 
solid tumors has been one of the main barriers in biomarker discovery [123] one of the main 
reasons is possibly the difficulty in getting access to the tissues. Researchers have now 
shown that micro-RNA signature circulating in blood can be used for lung cancer diagnosis 
more than two years — 28 months — before spiral computed tomography (CT) can detect 
the cancer [124]. Noninvasive prenatal detection of fetal chromosomal aneuploidies is 
possible by using maternal plasma [125].  
 
With sensitive enough technique, molecular information released into the circulation system 
would be revealed with surprises, such as the DNA of a biological father, through fetus and 
placenta, into mother’s blood. Biobank, where most of the samples are blood, not tissues, 
would be an invaluable resource for molecular epidemiologic studies that previously 
regarded as not possible with blood samples. 
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